Expression and prognostic significance of the PD‐1/PD‐L1 pathway in AIDS‐related non‐Hodgkin lymphoma

Documenti analoghi

• Co‐Expression of MHC‐II and ANXA1: Mediators of PD‐1/PD‐L1 Therapy Resistance in Breast Cancer
  di: Hao Wang, et al.
  Pubblicazione: (2025)
• The risk of treatment‐related toxicities with PD‐1/PD‐L1 inhibitors in patients with lung cancer
  di: Hao Hu, et al.
  Pubblicazione: (2024)
• High Antigenicity for Treg Cells Confers Resistance to PD‐1 Blockade Therapy via High PD‐1 Expression in Treg Cells
  di: Hiroaki Matsuura, et al.
  Pubblicazione: (2025)
• Intestinal Low‐Dose Radiation to Overcome PD‐1 Resistance in Pediatric Relapsed/Refractory Hodgkin Lymphoma
  di: Shubham Sahni, et al.
  Pubblicazione: (2026)
• Feasibility of Endobronchial Ultrasound Guided Miniforceps Biopsy for PD‐L1 Expression and Quantitative Tissue Analysis
  di: Max T. Wayne, et al.
  Pubblicazione: (2024)